Revvity, NET1169250UC, R(+)7-hydroxy DPAT, [ H], 250 µCi

Overview
7-OH-DPAT acts as a selective agonist at the dopamine D3 receptor. This receptor belongs to a group of GPCRs and is a potential drug target for schizophrenia, drug addiction, and Parkinson's disease.
We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.
Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. Concentration-1 mCi/ml
Molecular Weight-247
Specific Activity->100 Ci/mmol (>3700 GBq/mmol)
CAS Number-82730-72-1
Application-Drug Discovery & Development
Brand-NEN Radiochemicals
Buffer/Solvent-Ethanol
Detection Modality-Radiometric
Label Position-Specifically Labeled
Molecular Formula-C16H25NO
Packaging-NENSure vial
Radioisotope-3 H
Receptor-Dopamine
Shipping Information-Dry Ice
Shipping Conditions-Shipped in Dry Ice
Special Ordering Information-This is a radioactive product - shipping address must have a license to receive radioactive materials.
Storage Conditions--20°C
Therapeutic Area-CNS & Neurologic
Unit Size-250 µCi